Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19071647 | CANCER TREATMENTS USING MODIFIED FATTY ACIDS AND THE CARRIERS TO ADMINISTER THEM | March 2025 | July 2025 | Allow | 4 | 2 | 0 | No | No |
| 19039164 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | January 2025 | November 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18652164 | SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOF | May 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18184077 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | March 2023 | May 2025 | Allow | 26 | 3 | 1 | No | No |
| 18116891 | CO-CRYSTALS OR SALTS OF PSILOCIN AND METHODS OF TREATMENT THEREWITH | March 2023 | October 2025 | Allow | 32 | 4 | 1 | No | No |
| 18162990 | PHARMACEUTICAL COMPOSITIONS CONTAINING HEMP EXTRACT FOR ADMINISTRATION TO FELINES AND RELATED METHODS | February 2023 | June 2025 | Allow | 29 | 4 | 0 | No | No |
| 18146756 | HYDRALAZINE COMPOSITIONS AND METHODS | December 2022 | June 2024 | Allow | 17 | 2 | 0 | No | No |
| 18065772 | STABLE FORMULATIONS OF SHR0302 | December 2022 | September 2024 | Allow | 21 | 3 | 0 | No | No |
| 18000712 | CRYSTALLINE FORMS OF 5-[(1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL]-2-PHENYL-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDOL-7-AMINE | December 2022 | March 2026 | Allow | 40 | 2 | 0 | No | No |
| 17999627 | COMPOUNDS | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17986797 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | November 2022 | October 2025 | Allow | 36 | 5 | 0 | Yes | No |
| 17924220 | SALT AND CRYSTAL FORMS OF 4-AMINO-5-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZO[D]IMIDAZOL-2-YL)THIENO[2,3-B]PYRIDIN-6(7H)-ONE | November 2022 | January 2026 | Allow | 38 | 2 | 0 | No | No |
| 18049952 | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINS | October 2022 | June 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17918374 | METHODS OF USING SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF SICKLE CELL DISEASE | October 2022 | March 2026 | Abandon | 41 | 2 | 0 | Yes | No |
| 17918312 | COMPOSITION COMPRISING TRABECTEDIN AND AN AMINO ACID | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17956553 | SK CHANNEL POSITIVE ALLOSTERIC MODULATORS | September 2022 | January 2025 | Allow | 28 | 3 | 1 | No | No |
| 17956727 | FAPI DIMER COMPOUND, FAPI DIMER-BASED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENT FOR TUMOR DIAGNOSIS, AND PREPARATION METHOD AND USE THEREOF | September 2022 | February 2024 | Allow | 17 | 2 | 0 | No | No |
| 17907252 | NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17914157 | TRIAZOLONE COMPOUNDS | September 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17797804 | POLYMORPH OF EP4 RECEPTOR ANTAGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | August 2022 | December 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17881442 | COMPOUNDS USEFUL AS T CELL ACTIVATORS | August 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17795056 | SOLID STATE FORMS OF ASCIMINIB AND PROCESSES FOR THE PREPARATION THEREOF | July 2022 | February 2026 | Allow | 42 | 2 | 1 | Yes | No |
| 17837619 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17830714 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | June 2022 | December 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17714500 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | April 2022 | March 2025 | Abandon | 36 | 2 | 2 | Yes | No |
| 17707134 | CANNABIS LIMITS CANCER STEM CELL GROWTH IN POORLY DIFFERENTIATED CANCERS | March 2022 | December 2025 | Abandon | 45 | 4 | 1 | No | No |
| 17697281 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | March 2022 | May 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17629321 | ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS | January 2022 | February 2026 | Allow | 48 | 3 | 0 | No | No |
| 17628354 | EMULSIFIABLE CONCENTRATE FORMULATIONS AND THEIR USES | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17628542 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | January 2022 | January 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17620464 | CRYSTAL FORM AND SALT OF QUINAZOLINE COMPOUND AND PREPARATION METHOD THEREOF | December 2021 | October 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17618157 | CARBACHOL-BRIMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | December 2021 | October 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17545386 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN | December 2021 | January 2026 | Allow | 49 | 3 | 1 | No | No |
| 17615907 | INHIBITORS OF SARM1 | December 2021 | December 2025 | Allow | 48 | 2 | 1 | No | No |
| 17615659 | HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOF | December 2021 | June 2025 | Allow | 42 | 1 | 1 | No | No |
| 17595746 | TREATMENT OF INFANTILE HEMANGIOMA | November 2021 | February 2026 | Allow | 50 | 3 | 0 | Yes | No |
| 17526129 | FORMS OF METHYL {4,6-DIAMINO-2-[1 (2-FLUOROBENZYL)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE | November 2021 | September 2025 | Allow | 46 | 2 | 1 | No | No |
| 17594737 | CRYSTALLIZATION OF SMAC MIMIC USED AS IAP INHIBITOR AND PREPARATION METHOD THEREOF | October 2021 | January 2026 | Abandon | 51 | 2 | 0 | Yes | No |
| 17606542 | METHODS FOR TREATING AGAINST VIRUSES | October 2021 | October 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17604806 | SUSTAINED RELEASE FORMULATIONS | October 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17604732 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASES | October 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
| 17603762 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17602736 | CRYSTAL FORM OF EGFR INHIBITOR AND PREPARATION METHOD THEREOF | October 2021 | November 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17601790 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | October 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17601640 | DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE | October 2021 | January 2026 | Allow | 52 | 4 | 0 | No | No |
| 17487078 | ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF | September 2021 | July 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17441937 | COMPOUNDS AND USES THEREOF | September 2021 | December 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17441405 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17440319 | COMPOUND AND DIAGNOSTIC SYSTEM COMPRISING SAID COMPOUND FOR THE GUSTATORY DETECTION OF INFLAMMATIONS IN THE ORAL CAVITY | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17440246 | METHODS USING MEDIUM CHAIN TRIGLYCERIDES ADMINISTERED PRIOR TO A MEAL TO DECREASE POSTPRANDIAL GLUCOSE FROM THE MEAL | September 2021 | October 2025 | Allow | 49 | 4 | 0 | No | No |
| 17440229 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA USING 6,8-BISBENZYLTHIO-OCTANOIC ACID | September 2021 | July 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17440021 | METHODS USING ADMINISTRATION OF MEDIUM CHAIN TRIGLYCERIDES (MCT) PRIOR TO A MEAL TO INCREASE KETONE PRODUCTION FROM THE MCTS | September 2021 | November 2025 | Allow | 50 | 5 | 0 | Yes | No |
| 17310996 | MODULATORS OF AMPA RECEPTOR SIGNALING | September 2021 | March 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17435668 | COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17310930 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | August 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17433808 | TREATMENT OF ALZHEIMER'S DISEASE | August 2021 | July 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17432870 | PYRIDINE N-OXIDE COMPOUND AND PEST CONTROL AGENT | August 2021 | July 2025 | Allow | 47 | 2 | 1 | No | No |
| 17431634 | COMPOSITIONS COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR USE IN TREATING MENTAL DISORDERS | August 2021 | June 2024 | Abandon | 34 | 0 | 0 | No | No |
| 17400795 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | August 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17430287 | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE | August 2021 | January 2026 | Allow | 53 | 3 | 1 | No | No |
| 17428800 | IMPROVEMENTS IN OR RELATING TO SULFUR BASED PESTICIDES | August 2021 | February 2026 | Allow | 54 | 3 | 1 | No | No |
| 17391361 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17391620 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | May 2025 | Allow | 46 | 2 | 1 | No | No |
| 17391364 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17426047 | AKT INHIBITOR | July 2021 | January 2026 | Allow | 53 | 3 | 1 | No | No |
| 17425495 | CRYSTAL FORM OF 1,2,3-TRIAZOLO[1,5-A]PYRAZINES DERIVATIVE AND PREPARATION METHOD FOR CRYSTAL FORM | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17425140 | BRM/BRG1 INHIBITORS AND USES THEREOF | July 2021 | March 2026 | Allow | 56 | 4 | 1 | No | No |
| 17425041 | BRM/BRG1 INHIBITORS AND USES THEREOF | July 2021 | August 2025 | Allow | 49 | 2 | 1 | No | No |
| 17423545 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASE WITH MATRIX METALLOPROTEINASE INHIBITORS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17423060 | INDOLE MOLECULES AND USE THEREOF IN THE INHIBITION OF DNA POLYMERASES | July 2021 | March 2026 | Allow | 56 | 4 | 0 | No | No |
| 17310044 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISORDERS | July 2021 | December 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17417827 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | June 2021 | December 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 17416086 | THERAPIES FOR SQUAMOUS CELL CARCINOMAS | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17415681 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | June 2021 | April 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17312667 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | June 2021 | May 2025 | Allow | 48 | 2 | 0 | No | No |
| 17311391 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ALCOHOL COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | June 2021 | December 2025 | Abandon | 54 | 2 | 1 | No | Yes |
| 17299463 | CRYSTALLINE FORMS OF MULTICYCLIC COMPOUNDS AND USES THEREOF | June 2021 | January 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17299438 | COMPOSITIONS AND METHODS FOR CLEANING, DECONTAMINATION AND TREATING SUBJECTS EXPOSED TO CHEMICAL IRRITANTS | June 2021 | February 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17299164 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | June 2021 | April 2025 | Allow | 46 | 2 | 0 | No | No |
| 17299189 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | June 2021 | November 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17309485 | COMPOSITION AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER | June 2021 | May 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17298409 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | May 2021 | January 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17297984 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | May 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17330200 | HYDANTOIN DERIVATIVE | May 2021 | May 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17295490 | APPLICATION OF CHIDAMIDE | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17058587 | THERAPEUTIC AGENT FOR TREATING DIFFUSE GASTRIC CANCER | May 2021 | June 2025 | Abandon | 54 | 2 | 0 | Yes | No |
| 17293506 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | May 2021 | October 2024 | Allow | 41 | 2 | 0 | No | No |
| 17293381 | USE OF DISULFIRAM AND OTHER COMPOUNDS TO TREAT CANCERS WITH LOSS OF CHROMOSOME 16Q AND/OR LOW EXPRESSION OF METALLOTHIONEIN PROTEINS | May 2021 | May 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17293362 | METHODS FOR MANIPULATING CELL STATE TRANSITIONS IN CANCER | May 2021 | February 2026 | Allow | 58 | 4 | 0 | Yes | No |
| 17291904 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | May 2021 | September 2025 | Allow | 52 | 4 | 1 | No | No |
| 17288934 | NEW ALKOXYAMINOPYRIDINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17289162 | TARGETING THE ONCOGENIC TRANSCRIPTION FACTOR STAT5 WITH MINERALOCORTICOID ANALOGUES | April 2021 | August 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17240969 | COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA | April 2021 | December 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17287861 | Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 Modulators | April 2021 | December 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 17286529 | USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING DIABETIC PERIPHERAL NEUROPATHY OR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | April 2021 | August 2025 | Allow | 52 | 3 | 0 | No | No |
| 17285973 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17286282 | DOSAGE REGIME | April 2021 | November 2025 | Allow | 55 | 4 | 0 | No | No |
| 17232012 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | April 2021 | August 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17284855 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | July 2024 | Allow | 40 | 2 | 0 | No | No |
| 17284816 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BRAUN, MADELINE E.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BRAUN, MADELINE E works in Art Unit 1624 and has examined 93 patent applications in our dataset. With an allowance rate of 63.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner BRAUN, MADELINE E's allowance rate of 63.4% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BRAUN, MADELINE E receive 1.99 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BRAUN, MADELINE E is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.2% benefit to allowance rate for applications examined by BRAUN, MADELINE E. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.5% of applications are subsequently allowed. This success rate is in the 64% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 54.7% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 27.1% of allowed cases (in the 95% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.